secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2026-06-26T21:07:54+00:00
Accession:  0001104659-26-078323
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Animal Health appoints Daniel Bendheim as CEO effective July 1, 2026, with performance-based RSU grant
--------------------------------------------------------------------------------

- Daniel Bendheim appointed CEO & President effective July 1, 2026; base salary $850k, target bonus 50% of salary.
- Granted 300,000 performance-based RSUs vesting based on 90-day average stock price from $70 to $100+ by June 30, 2031.
- Severance: 18 months COBRA if terminated without cause; 6 months base salary for death/disability.
- Employment agreement includes confidentiality, non-compete, non-solicitation, non-disparagement covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000110465926078323/0001104659-26-078323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000110465926078323/tm2619111d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-078323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer